



## **DRAFT Agenda**

### **Workshop**

## **Antibiotics and their alternatives – fixing and feeding the pipeline**

**Date: 4 April 2014 Brussels**

**Location: MADOU Auditorium**

### ***Rationale for the workshop***

- On 3 April (the preceding day) the Joint programming initiative on antimicrobial resistance (JPIAMR) will launch its strategic research agenda (SRA). The launch event will consist of the official launch ceremony followed by a workshop focussed on "Implementing a global research agenda for AMR".
- The development of new antibiotics is one of the main areas in the SRA and this is also the topic of the first joint call of JPIAMR (to be launched in January 2014). Recently, EU research funding has increased considerably in this particular area, via FP7 collaborative research projects as well as via IMI's New Drugs for Bad Bugs programme. Within Europe AMR research is financed by the EU, national funders and private companies, and this research is implemented by researchers in academia, SMEs as well as in large pharmaceutical industries.
- This workshop aims to promote dialogue and collaboration amongst the different actors along the “value chain“ in order to ensure synergies and maximise the impact of investments by effective exploitation of results.

### ***Objectives***

- To present research results of recently completed FP7 projects that aimed to develop novel targets and drugs against Gram negative bacteria
- To present the development and discovery platforms that are being set up within IMI projects
- To present new collaborative research projects (with an SME focus) on the development of new drugs, vaccines and alternative methods
- To present the 1<sup>st</sup> joint call of the JPIAMR
- To discuss the most efficient ways of ensuring exploitation of results in order to feed the pipeline.

## **Programme:**

9:00-9:10	Welcome address and introduction <b>Ruxandra Draghia-Akli</b> <i>Director, Directorate General for Research and Innovation, European Commission</i>
9:10-9:20	Introduction <b>Richard Bergström</b> <i>Director General, EFPIA</i>
9:20-9:30	JPIAMR presentation of priority topic A (development of antibiotics and their alternatives) and 1st joint call <b>Mats Ulfendahl</b> <i>MB Chair, Swedish research Council</i>

### **Session 1 Recently completed FP7 projects that aimed to develop novel targets and drugs against Gram negative bacteria**

#### **Moderation:**

**Ruxandra Draghia-Akli**, Director, Directorate General for Research and Innovation, European Commission

**Marco Cavaleri**, Head of Anti-infectives and Vaccines, EMA

9:30-9:50	Identification, Characterisation and exploitation of novel Gram-negative drug targets - AEROPATH outcome and uptake of results <b>Bill Hunter (confirmed)</b> <i>University of Dundee (UK)</i>
9:50-10:10	Identification and validation of novel drug targets in Gram-negative bacteria by global search: a trans-system approach – AntiPathoGN outcome and uptake of results <b>Xavier Daura (confirmed)</b> <i>Universitat Autònoma de Barcelona (ES)</i>
10:10-10:30	Exploiting Gram-negative cell division targets in the test tube to obtain antimicrobial compounds - DIVINOCELL outcome and uptake of results <b>Miguel Vicente (confirmed)</b> <i>Agencia Estatal Consejo Superior de Investigaciones Científicas (ES)</i>
10:30-10:50	Novel Approaches to Bacterial Target Identification Validation and Inhibition NABATIVI outcome and uptake of results <b>Alessandra Bragonzi (confirmed)</b>

	<i>San Raffaele Scientific Institute (IT)</i>
10:50-11:05	Discussion
11:05-11:25	Coffee Break

<b>Session 2 IMI funded projects of the New drugs for bad bugs programme</b>	
<b>Moderation:</b> <i>Michel Goldman, Executive Director, IMI</i> <i>Magda Chlebus, Director of Science Policy, EFPIA</i>	
11:25-11:30	Short Introduction of IMI and its ND4BB programme  <i>Michel Goldman</i> <i>Executive Director, IMI</i>
11:30-11:50	Combatting Bacterial Resistance in Europe COMBACTE (IMI) presentation of activities <i>Odin Naderer, GSK or Seamus O'Brien, AZ (tbc)</i> <i>GSK or AstraZeneca</i>
11:50-12:05	Molecular basis of the bacterial cell wall permeability TRANSLOCATION (IMI) presentation of activities <i>Rob Stavenger (or alternatively Matthias Winterhalter?)(tbc)</i> <i>GlaxoSmithKline</i>
12:05-12:20	ENABLE (IMI) presentation of activities  <b>Anders Karlén (confirmed)</b> <i>Uppsala University (SE)</i>
12:20-12:35	Topic 4 (business model) (IMI) presentation of activities  <b>John Rex (tbc)</b> <i>Head of Infection, Global Medicines Development, AstraZeneca</i>
12:35-12:50	Discussion
12:50- 13:45	Lunch

**Session 3 :Novel SME-driven projects on the development of new drugs, vaccines and alternative methods**

**Moderation:**

*Line Matthiessen, Head of Unit, Directorate General for Research and Innovation, European Commission*

*Titta Rosvall-Puplett, Executive Director, EBE*

13:45-14:00	New AntiBacterials with Inhibitory activity on Aminoacyl-tRNA Synthetases: NABARSI presentation of activities <b>Lluís Ribas de Pouplana (confirmed)</b> <i>CSO, Omnia Molecular SL (ES)</i>
14:00-14:15	Development of Group B Streptococcal vaccine to alleviate emerging antibiotic resistance through elimination of current prophylactic antibiotic strategies in GBS prevention: NEOSTREP presentation of activities <b>Per Fischer (confirmed)</b> <i>CEO, Minervax (DK)</i>
14:15-14:30	comBinig cELLular and humoral immunE RespOnses as a vaccine strategy against staPHhylOcoccus aureus pathogen: BELLEROPHON presentation of activities <b>Alexandre Le Vert (CEO)/Fergal Hill (confirmed)</b> <i>Imaxio (FR)</i>
14:30-14:45	Oral Vaccination against Clostridium Difficile Infection: CD-VAX presentation of activities <b>Jonathan Kearsey (confirmed)</b> <i>Managing Director, Leads To Development (FR)</i>
14:45-15:00	Evaluation of Phage Therapy for the Treatment of Burn Wound Infection: PHAGOBURN presentation of activities <b>Jérôme Gabard (confirmed)</b> <i>CEO, Pherecydes Pharma (FR)</i>
15:00-15:15	Discussion

15:15-15:35	Coffee break
15:35-16:50	<p>Open discussion/panel discussion on how to stimulate the development of a healthy pipeline of antibiotics.</p> <p><b>Moderation:</b></p> <p>Discussion will among others address the following questions:</p> <ul style="list-style-type: none"> <li>- Are we using the right funding instruments in order to feed the pipeline?</li> <li>- Do we have the right tools in place to ensure efficient exploitations of results?</li> <li>- Are meetings like today sufficient /useful?</li> </ul>
16:50-17:00	<p>Concluding remarks</p> <p><b>Ruxandra Draghia-Akli</b>, Director, Directorate General for Research and Innovation, European Commission</p>